重型再生障碍性贫血抗胸腺球蛋白治疗后伴垂体功能减退治疗研究

    Case Report and Review: Hypopituitarism after the ATG Treatment for the Patient of Severe Aplastic Anemia

    • 摘要: 目的 了解在使用ATG行强化免疫抑制治疗重型再障的过程中引起垂体功能减退的原因及相关并发症的防治。方法 临床医师总结 1 例应用ATG引起垂体功能减退的诊治过程及对国内外文献进行查阅。结果 ATG可以引起垂体功能减退,应引起临床注意。结论 在临床诊治重型再生障碍性贫血时,要特别注意潜在的并发症,从而降低治疗风险,提高疗效。

       

      Abstract: OBJECTIVE To find out the cause of hypopituitarism induced by ATG in the process of intensive immunosuppressive therapy (IST) for severe aplastic anemia, and to prevent related complications. METHODS A case of hypopituitarism induced by ATG was chosen, which clinical physician participated in the whole treatment and literatures were reviewed. RESULTS ATG can induce hypopituitarism, which should bring enough attentions in clinical. CONCLUSION In the clinical diagnosis and treatment of severe aplastic anemia, we should pay more attention to the potential complications, so as to reduce the risk of treatment, improve the outcome of treatment.

       

    /

    返回文章
    返回